Skip to main content

Table 4 Certainty in the assessment of efficacy outcomes for anti-calcitonin gene-related peptide monoclonal antibodies for prevention in chronic migraine

From: Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

  Certainty assessment Certainty
Number of studies Study design Risk of bias Inconsistency Indirectness Imprecision Other considerations
Erenumab
 70 monthly sc 1 RCT not serious seriousa not serious not serious none MEDIUM
 140 monthly sc 1 RCT not serious seriousa not serious not serious none MEDIUM
Fremanezumab
 675 quarterly sc 1 RCT not serious seriousa not serious not serious none MEDIUM
 675 ld + 225 quarterly sc (except functional improvement) 2 RCT not serious not serious not serious not serious none HIGH
 675 ld + 225 quarterly sc (functional improvement) 1 RCT not serious seriousa not serious not serious none MEDIUM
Galcanezumab
 240 mg ld + 120 mg monthly sc 1 RCT not serious seriousa not serious not serious none MEDIUM
 240 mg monthly sc 1 RCT not serious seriousa not serious not serious none MEDIUM
  1. aInconsistency because of lack of replication
  2. sc subcutaneous, ld loading dose, RCT randomized controlled trial